Patents by Inventor Kenneth Albert Brameld

Kenneth Albert Brameld has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunoproteasome inhibitors
    Patent number: 12312370
    Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: October 17, 2023
    Date of Patent: May 27, 2025
    Assignee: Principia Biopharma Inc.
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • Quinolone derivatives as fibroblast growth factor receptor inhibitors
    Patent number: 12162882
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: June 30, 2023
    Date of Patent: December 10, 2024
    Assignee: PRINCIPIA BIOPHARMAC, INC.
    Inventors: Erik Verner, Kenneth Albert Brameld
  • Immunoproteasome inhibitors
    Patent number: 12024531
    Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: July 2, 2024
    Assignee: Principia Biopharma Inc.
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • Immunoproteasome Inhibitors
    Publication number: 20240199655
    Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: October 17, 2023
    Publication date: June 20, 2024
    Applicant: Principia Biopharma Inc.
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors
    Publication number: 20240092777
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: June 30, 2023
    Publication date: March 21, 2024
    Applicant: Principia Biopharma Inc.
    Inventors: Erik Verner, Kenneth Albert Brameld
  • Immunoproteasome inhibitors
    Patent number: 11827656
    Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: November 28, 2023
    Assignee: Principia Biopharma Inc.
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • IMMUNOPROTEASOME INHIBITORS
    Publication number: 20230133165
    Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: November 14, 2018
    Publication date: May 4, 2023
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • Immunoproteasome Inhibitors
    Publication number: 20220073538
    Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: November 16, 2021
    Publication date: March 10, 2022
    Applicant: Principia Biopharma Inc.
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • Immunoproteasome inhibitors
    Patent number: 11225493
    Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: January 18, 2022
    Assignee: Principia Biopharma Inc.
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • Immunoproteasome inhibitors
    Patent number: 11154563
    Abstract: Provided herein are compounds, such as a compound of Formula (I), as described herein, or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: October 26, 2021
    Assignee: Principia Biopharma Inc.
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • Quinolone Derivatives as Fibroblast Growth Factor Inhibitors
    Publication number: 20210292323
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: May 3, 2021
    Publication date: September 23, 2021
    Applicant: Principia Biopharma Inc.
    Inventors: Erik Verner, Kenneth Albert Brameld
  • Quinolone derivatives as fibroblast growth factor receptor inhibitors
    Patent number: 11078199
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: August 3, 2021
    Assignee: PRINCIPIA BIOPHARMA, INC.
    Inventors: Erik Verner, Kenneth Albert Brameld
  • IMMUNOPROTEASOME INHIBITORS
    Publication number: 20200277312
    Abstract: Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: November 14, 2018
    Publication date: September 3, 2020
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • LMP7 inhibitors
    Patent number: 10654843
    Abstract: The present disclosure provides compounds that are Large Multifunctional Protease 7 (LMP7) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of LMP7. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: May 19, 2020
    Assignee: Principia Biopharma Inc.
    Inventors: Timothy Owens, Kenneth Albert Brameld
  • Quinolone derivatives as FGFR inhibitors
    Patent number: 10538517
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: January 21, 2020
    Assignee: Principia Biopharma, Inc.
    Inventors: Kenneth Albert Brameld, Erik Verner
  • IMMUNOPROTEASOME INHIBITORS
    Publication number: 20190336515
    Abstract: Provided herein are compounds, such as a compound of Formula (I), as described herein, or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: January 16, 2018
    Publication date: November 7, 2019
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS
    Publication number: 20190233418
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: April 12, 2019
    Publication date: August 1, 2019
    Inventors: Erik VERNER, Kenneth Albert BRAMELD
  • Quinolone derivatives as fibroblast growth factor receptor inhibitors
    Patent number: 10294223
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: May 21, 2019
    Assignee: PRINCIPIA BIOPHARMA, INC.
    Inventors: Erik Verner, Kenneth Albert Brameld
  • LMP7 INHIBITORS
    Publication number: 20180208589
    Abstract: The present disclosure provides compounds that are Large Multifunctional Protease 7 (LMP7) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of LMP7. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: June 18, 2015
    Publication date: July 26, 2018
    Inventors: Timothy Owens, Kenneth Albert Brameld
  • QUINOLONE DERIVATIVES AS FGFR INHIBITORS
    Publication number: 20180155340
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: May 18, 2016
    Publication date: June 7, 2018
    Inventors: Kenneth Albert BRAMELD, Erik VERNER